DG DISPATCH - APA: Paroxetine Effective Against Hot Flushes in Survivors of Breast Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - APA: Paroxetine Effective Against Hot Flushes in Survivors of Breast Cancer

By Lara Pullen
Special to DG News

CHICAGO, IL -- May 19, 2000 -- A recent paroxetine study demonstrated substantial reduction in hot flushes and improvement in menopausal symptoms among breast cancer survivors.

At the 2000 Annual Meeting of the American Psychiatric Association, in Chicago, IL, Kate Beebe, MD, of SmithKline Beecham Pharmaceuticals, presented the results of a five-week, open-label trial designed to evaluate changes in mood, anxiety, sleep, sexual function, and overall quality of life in perimenopausal with paroxetine.

The study included 27 women over the age of 18 who had a history of breast cancer. The patients had a minimum of 14 hot flushes per week over at least one month. Patients undergoing cytotoxic chemotherapy, hormonal therapy other than tamoxifen, antidepressants, or other therapies for hot flushes (except for Vitamin E) were excluded from the study.

The study found a 67 percent mean reduction in hot flushes. Of the 27 women, 67 percent responded with a greater than 50 percent reduction in the daily number of hot flushes (the typical placebo response is 27 percent). Patients treated with paroxetine experienced a significant improvement in overall quality of life and paroxetine was generally well tolerated.

More than 80 percent of enrolled women chose to continue treatment at study conclusion.
Results from a large double-blind placebo-controlled trial of paroxetine are expected this year.

Related links: Paroxetine.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities